BridgeBio Pharma (NASDAQ:BBIO) Director Andrea Ellis Sells 64,921 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 64,921 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the completion of the transaction, the director directly owned 18,589 shares of the company’s stock, valued at approximately $1,205,868.43. The trade was a 77.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

BridgeBio Pharma Price Performance

Shares of NASDAQ BBIO opened at $65.36 on Friday. The stock has a market capitalization of $12.67 billion, a P/E ratio of -17.29 and a beta of 1.13. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The business’s 50 day moving average is $73.64 and its two-hundred day moving average is $65.22.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same period last year, the business posted ($1.40) EPS. The business’s revenue for the quarter was up 2521.2% on a year-over-year basis. As a group, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Brooklands Fund Management Ltd bought a new stake in shares of BridgeBio Pharma during the fourth quarter valued at approximately $210,348,000. Price T Rowe Associates Inc. MD increased its holdings in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after purchasing an additional 2,261,181 shares during the period. Janus Henderson Group PLC increased its holdings in BridgeBio Pharma by 25.8% during the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after purchasing an additional 2,259,378 shares during the period. Norges Bank bought a new stake in BridgeBio Pharma during the 2nd quarter valued at $84,488,000. Finally, Wellington Management Group LLP grew its position in shares of BridgeBio Pharma by 130.4% during the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock worth $179,654,000 after buying an additional 1,329,537 shares in the last quarter. 99.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BBIO shares. HC Wainwright raised their target price on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Sanford C. Bernstein began coverage on shares of BridgeBio Pharma in a research report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective on the stock. Raymond James Financial set a $89.00 target price on BridgeBio Pharma and gave the company an “outperform” rating in a research report on Thursday, February 12th. Truist Financial upped their target price on BridgeBio Pharma from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Barclays started coverage on BridgeBio Pharma in a research note on Wednesday, January 28th. They set an “overweight” rating for the company. Twenty-two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $82.50.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.